House Lawmaker Raises Concerns Over FDA's Fast-Track Drug Review Program

Rep. Jake Auchincloss questions legal authority and ethics of the agency's 'Commissioner's National Priority Voucher' initiative.

Feb. 3, 2026 at 6:15pm

Got story updates? Submit your updates here. ›

A Democratic lawmaker is raising new concerns about a Food and Drug Administration program designed to drastically shorten the review of certain drugs. Rep. Jake Auchincloss of Massachusetts took issue with the agency's handling of the 'Commissioner's National Priority Voucher' program, questioning its legal underpinnings and whether senior officials involved are complying with federal ethics rules.

Why it matters

The FDA's fast-track drug review program has become a point of controversy, with several senior staffers declining to sign off on drug approvals going through the program. The concerns raised by Rep. Auchincloss highlight broader questions about transparency, conflicts of interest, and the FDA's authority to establish such initiatives without Congressional approval.

The details

In his letter, Auchincloss asserts that the FDA has failed to publish or disclose financial disclosure forms for eight senior FDA officials who vote on which drugs should receive priority vouchers. He also questions whether the FDA had the legal authority to establish the voucher program without action from Congress. The lawmaker instructed the agency to 'affirm or refute' his findings.

  • On February 3, 2026, Rep. Jake Auchincloss sent a letter raising concerns about the FDA's fast-track drug review program.
  • The FDA is scheduled to hold an employee town hall on the 'Commissioner's National Priority Voucher' program on February 3, 2026.

The players

Rep. Jake Auchincloss

A Democratic lawmaker from Massachusetts who is raising concerns about the FDA's fast-track drug review program.

FDA Commissioner Marty Makary

The FDA Commissioner who has championed the 'Commissioner's National Priority Voucher' program as part of his goal to 'cut red tape' and 'challenge assumptions' at the agency.

Dr. Sara Brenner

The FDA's Deputy Commissioner who is part of the group that votes on which drugs should receive priority vouchers.

Dr. Vinay Prasad

An FDA official who oversees vaccines and is part of the group that votes on priority vouchers.

Dr. Tracy Beth Hoeg

The FDA's drug center director who is part of the group that votes on priority vouchers.

Got photos? Submit your photos here. ›

What they’re saying

“The public must have transparency about the 'voucher' program, under which drug approvals have been made almost wholly and in an unprecedented manner by the FDA's political leadership.”

— Rep. Jake Auchincloss

What’s next

The FDA is scheduled to hold an employee town hall on the 'Commissioner's National Priority Voucher' program on February 3, 2026, where these concerns may be further addressed.

The takeaway

The concerns raised by Rep. Auchincloss highlight broader questions about transparency, conflicts of interest, and the FDA's authority to establish fast-track drug review programs without Congressional approval. This issue is likely to remain a point of controversy as the agency defends the legality and ethics of its 'Commissioner's National Priority Voucher' initiative.